Market revenue in 2021 | USD 154.3 million |
Market revenue in 2030 | USD 342.0 million |
Growth rate | 9.2% (CAGR from 2021 to 2030) |
Largest segment | Blood |
Fastest growing segment | Blood |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Blood, Saliva, Urine, Cerebrospinal Fluid |
Key market players worldwide | Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Guardant Health Inc, Qiagen NV, Johnson & Johnson, Labcorp Holdings Inc, Biocept Inc, Roche, MDxHealth SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to body fluid collection and diagnostics market will help companies and investors design strategic landscapes.
Blood was the largest segment with a revenue share of 74.85% in 2021. Horizon Databook has segmented the Australia body fluid collection and diagnostics market based on blood, saliva, urine, cerebrospinal fluid covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia body fluid collection and diagnostics market, including forecasts for subscribers. This country databook contains high-level insights into Australia body fluid collection and diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account